Comparative Pharmacology
Head-to-head clinical analysis: OMNIPAQUE 70 versus OSMOVIST 240.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OMNIPAQUE 70 versus OSMOVIST 240.
OMNIPAQUE 70 vs OSMOVIST 240
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast by increasing the density of blood vessels and organs.
Nonionic iodinated contrast medium that attenuates X-rays is excreted unchanged in urine; increases density of blood vessels and tissues to enhance radiological visualization.
1.5-2.0 mL/kg IV for contrast enhanced CT, max 150 mL; intra-arterial: 5-40 mL per injection depending on procedure.
Intravenous bolus injection: 0.5 mL/kg to 1 mL/kg of Osnovist 240 (240 mg iodine/mL) for CT enhancement, up to a maximum of 150 mL per dose.
None Documented
None Documented
Terminal elimination half-life: 1-2 hours in normal renal function; prolonged in renal impairment (up to 20-30 hours in severe dysfunction).
Terminal elimination half-life approximately 2 hours (range 1.5–4 hours) in patients with normal renal function; prolonged in renal impairment proportional to creatinine clearance.
Renal: 100% unchanged via glomerular filtration. No biliary or fecal elimination.
Primarily renal (glomerular filtration); >95% of administered dose excreted unchanged in urine within 24 hours. Negligible biliary/fecal elimination (<5%).
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent